Tiziana Life Sciences

(NASDAQ: TLSA)
Healthcare  |  Biotechnology
3.49 0.35 11.15%
Stock Price | Sept. 25, 2020, 4 p.m.
0 Followers
Bid: 0.0
Ask: 0.0
Prev. Close: 3.14
52 Week Low: 1.54
52 Week High: 16.79
PE Ratio: 0.0
Dividend Yield: 0.0%

Company Summary

Tiziana Life Sciences PLC is involved in the business of developing novel therapeutics for cancer with a focus on late-stage growth and complementary diagnostic tools, with the capability of predicting disease aggressiveness and prognosis in breast cancer patients. The group also has interests, beyond pure oncology, in the discovery and development of monoclonal antibody-based biologics used to benefit patients with inflammatory and auto-immune disorders. The company has a single reporting segment, The Research, and Development of Biotechnological and Pharmaceutical Products. Its lead compound, milciclib (TZLS-201), is a molecule which blocks the action of specific enzymes involved in cell division as well as a number of other protein kinases.

Read more Read less

Recently Viewed Tickers

Free THE WEEKLY TOP 10

2 months ago